Annexon, Inc. (ANNX) SEC Filings & Earnings Calls

Going concern risk

“The Company has experienced losses and negative cash flows from operations since its inception and, as of June 30, 2026, had an accumulated deficit of approximately $1.0 billion.” · word for word

Financing dependency

“If the Company is not able to obtain the required funding for its operations or is not able to obtain funding on terms that are favorable to the Company, it could be forced to delay, reduce or eliminate its research and development programs.” · word for word

High R&D spend with no revenue; reliance on clinical success

“R&D expenses $46.6M; no product revenue”

Floating interest rate (SOFR+4.6%, floor 7.60%) exposes company to rising rate risk; financial covenants require minimum liquidity/revenue levels.

“Term loans bear interest at floating per annum rate equal to greater of (i) 1-Month CME Term SOFR plus 4.6% and (ii) 7.60%; includes financial covenants requiring maintenance of certain liquidity levels and/or minimum revenue levels”

No approved products; history of losses

“We do not have any products approved for sale, and we have not generated any revenue from product sales. We have incurred net losses each year since our inception.” · word for word

Dependence on future funding

“The Company’s future viability beyond that point is dependent on its ability to achieve development and regulatory milestones and obtain additional funding.” · word for word

Clinical trial risk

“The process of conducting the necessary clinical research, development and manufacturing to obtain regulatory approval is costly and time-consuming, and the successful development and approval of our product candidates is highly uncertain.” · word for word

Clinical trial risk: Phase 3 data for vonaprument in GA expected Q4 2026; failure could impact pipeline value.

“Topline Pivotal Phase 3 Data for Vonaprument for the Treatment of Geographic Atrophy (GA) Expected Q4 2026.” · word for word

Regulatory risk: Tanruprubart MAA under review; BLA submission pending; approval uncertainty.

“Tanruprubart EU Marketing Authorization Application (MAA) Under Review; BLA Submission with U.S./European FORWARD Data Expected in 2026.” · word for word

Clinical Development Risk

“We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.” · word for word

Capital Requirements Risk

“We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development programs.” · word for word

Regulatory Approval Risk

“The FDA has indicated that the generalizability package may not be sufficient to support BLA approval absent additional patient data.” · word for word

Clinical Trial Enrollment Risk

“We may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we identify or develop if we are unable to locate and enroll a sufficient number of eligible patients.” · word for word

Novel Therapeutic Approach Risk

“C1q inhibition is a novel therapeutic approach, which exposes us to certain risks.” · word for word

Pre-revenue biotech with clinical-stage pipeline; regulatory and trial execution risks.

“Pipeline milestones for GA, GBS, autoimmune; no approved products or revenue.”

Loss of experienced chairman could impact board oversight, but no immediate disruption expected.

“Mr. Wiggans will remain in his roles... until the conclusion of the 2026 Annual Meeting” · word for word

No new risk signals; standard forward-looking statements.

“Boilerplate risk factors in presentation.”

Clinical trial risk: pipeline programs may fail to meet endpoints, leading to impairment.

“Multiple registrational milestones in 2026; inherent uncertainty in clinical development”

Dilution risk from substantial share issuance; potential downward pressure on stock price.

“Issuance of 28.8M shares (including over-allotment) relative to existing float.”

Cash burn risk

“The Company has experienced losses and negative cash flows from operations since its inception and, as of September 30, 2025, had an accumulated deficit of $869.1 million.” · word for word

Dilution risk from ATM

“During the nine months ended September 30, 2025, the Company sold 5,235,959 shares of its common stock under the 2024 ATM program for net proceeds of approximately $13.5 million.” · word for word

Clinical trial failure risk for vonaprument and ANX1502; regulatory uncertainty for BLA submission.

“Dialogue with the FDA is also ongoing regarding the generalizability package supporting the U.S. Biologics License Application (BLA) submission.” · word for word